Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
News|Articles|January 1, 2025
Top 5 Podcast Episodes of 2024
Author(s)MHE Staff
2024's top podcast episodes includes a conversation with Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits.
Advertisement
- Loren McCaghy of Accenture Suggests Digital Engagement, Ease of Use as Key Drivers in Healthcare Provider and Payer Turnover
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.Listen here - A Deep Dive into Predictive and Generative AI with Lynn Carroll of HSBlox
In this month’s episode, Briana Contreras, an editor of MHE, chatted with Lynn Carroll, executive of HSBlox, about the difference between predictive and generative AI, yet how each works together in preventive healthcare.Listen here
- Sanjula Jain Urges a Comprehensive Approach to Address Alarming Rise in Cancer Cases Among Younger Populations
In this month’s episode of Tuning In to the C-Suite, Briana Contreras, an editor of Managed Healthcare Executive, got to chatting with Sanjula Jain, Ph.D., chief research officer at Trilliant Health.Listen here - Meet the Board: Optum Rx's David Calabrese Discusses New Role, Pharmacy Deserts, Medication Shortages and More
In the latest episode of the Meet the Board podcast series, Managing Editor, Peter Wehrwein, catches up with Chief Clinical Officer at Optum Rx and EAB member, David Calabrese, about his new role alongside his team's progress in improving quality, patient safety and health equity in healthcare.Listen Here - Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.Listen here
Advertisement
Related to this article
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Teen boys with obesity and lower baseline fitness were less likely to see MASLD resolve during a lifestyle program, a Belgian study found.
MassHealth's Katelyn Meyer, Pharm.D., says mandatory coverage, young patients and an unpredictable FDA make planning for new specialty drugs a challenge.
A truly transparent PBM arrangement starts with full disclosure of direct and indirect compensation.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The ripple effects of Medicare’s maximum fair price with Hiva Pourarsalan, Pharm.D. | AMCP Nexus 2026
2
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
3
How common is atopic dermatitis in the US? Not nearly as common as other research has shown, according to this study
4
Team-based reassessment helps most patients with borderline resectable lung cancer reach surgery after immunotherapy
5